Table 4 LVEF of patients in H group and HP group under various risk factors.
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
H group | HP group | P value | H group | HP group | P value | ||
|---|---|---|---|---|---|---|---|
N = 55 | N = 40 | N = 49 | N = 17 | ||||
Age ≥ 60 | CAD | ||||||
Baseline | 65.04 ± 2.03 | 64.68 ± 2.25 | 0.261 | Baseline | 64.88 ± 2.02 | 65.07 ± 1.54 | 0.725 |
3m | 63.83 ± 2.13 | 63.68 ± 2.08 | 0.709 | 3m | 63.21 ± 2.78 | 64.49 ± 2.31 | 0.252 |
6m | 62.77 ± 3.42 | 62.74 ± 3.43 | 0.872 | 6m | 61.44 ± 3.24 | 61.20 ± 3.62 | 0.683 |
9m | 61.15 ± 3.58 | 61.77 ± 3.79 | 0.258 | 9m | 60.73 ± 3.65 | 58.11 ± 3.97 | 0.037* |
12m | 58.89 ± 3.87 | 59.22 ± 3.46 | 0.237 | 12m | 59.59 ± 3.89 | 56.82 ± 4.21 | 0.021* |
N = 91 | N = 95 | N = 184 | N = 110 | ||||
|---|---|---|---|---|---|---|---|
Left chest wall radiotherapy | Anthracyclines | ||||||
Baseline | 65.01 ± 2.58 | 65.13 ± 1.97 | 0.721 | Baseline | 64.73 ± 2.57 | 64.83 ± 2.97 | 0.619 |
3m | 63.19 ± 3.17 | 63.28 ± 2.84 | 0.837 | 3m | 63.25 ± 2.43 | 62.91 ± 2.85 | 0.207 |
6m | 62.44 ± 3.95 | 62.52 ± 3.12 | 0.896 | 6m | 62.83 ± 3.99 | 60.15 ± 3.62 | < 0.001* |
9m | 61.29 ± 3.89 | 61.47 ± 3.71 | 0.623 | 9m | 60.94 ± 3.63 | 59.12 ± 3.61 | < 0.001* |
12m | 59.26 ± 4.45 | 59.08 ± 4.23 | 0.435 | 12m | 59.36 ± 4.28 | 57.79 ± 4.35 | < 0.001* |
